专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011153010A1 METHODS OF TREATMENT OF PANCREATIC CANCER 审中-公开
标题翻译：治疗胰腺癌的方法
公开(公告)号：WO2011153010A1
公开(公告)日：2011-12-08
申请号：PCT/US2011/037462
申请日：2011-05-20
申请人： ABRAXIS BIOSCIENCES, LLC , DESAI, Neil, P. , SOON-SHIONG, Patrick
发明人： DESAI, Neil, P. , SOON-SHIONG, Patrick
IPC分类号： A61K31/337 , A61K47/42 , A61K9/14 , A61P35/00
CPC分类号： A61K9/5169 , A61K31/16 , A61K31/337 , A61K31/436 , A61K31/4709 , A61K31/4745 , A61K31/506 , A61K31/513 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/69 , A61K31/7068 , A61K39/3955 , A61K45/06 , A61K2300/00
摘要： The present invention provides methods and compositions for treating pancreatic cancer in an individual who has been previously treated for pancreatic cancer (e.g., gemcitabine-based therapy) by administering a composition comprising nanoparticles that comprise a taxane and an albumin. The invention also provides combination therapy methods of treating pancreatic cancer (for example, in an individual who has been previously treated for pancreatic cancer) comprising administering to an individual an effective amount of a composition comprising nanoparticles that comprise a taxane and an albumin and another agent.
摘要翻译：本发明提供了通过给予包含包含紫杉烷和白蛋白的纳米颗粒的组合物预先治疗胰腺癌（例如吉西他滨的疗法）的个体中治疗胰腺癌的方法和组合物。本发明还提供了治疗胰腺癌的联合治疗方法（例如，在先前已经用于胰腺癌的个体中），包括向个体施用有效量的包含紫杉烷和白蛋白的纳米颗粒的组合物和另一种药剂。

2. 发明申请

WO2014031165A1 COMPOUNDS AND METHODS OF TREATING DIABETES 审中-公开
标题翻译：化合物和治疗糖尿病的方法
公开(公告)号：WO2014031165A1
公开(公告)日：2014-02-27
申请号：PCT/US2013/032052
申请日：2013-03-15
申请人： MEDIVATION TECHNOLOGIES, INC.
发明人： PROTTER, Andrew, Asher , CHAKRAVARTY, Sarvajit , GREEN, Michael, John
IPC分类号： A61K31/495 , A61K38/00 , A01N43/54 , A01N43/42 , C07D471/14
CPC分类号： C07D471/22 , A61K31/44 , A61K31/495 , C07D471/04 , C07D471/14 , C07D471/18 , C07D519/00 , A61K2300/00
摘要： Hydrogenated pyrido[4,3-b]indoles and pyrido [3, 4-b] indoles are described. The compounds may bind to and are antagonists of the adrenergic receptor a2A. The compounds may also bind to and are an antagonist of the adrenergic receptor α2β; or the compounds are not antagonists of the adrenergic receptor α2β and the compounds are administered in conjunction with a second agent that reduces, or is expected to reduce, blood pressure in an individual. The compounds may find use in therapy, e.g., to regulate blood glucose level, increase insulin secretion and treat diseases or conditions that are, or are expected to be, responsive to an increase in insulin production. Use of the compounds to treat type 2 diabetes is particularly described.
摘要翻译：描述了氢化吡啶并[4,3-b]吲哚和吡啶并[3,4-b]吲哚。该化合物可以与肾上腺素能受体a2A结合并且是拮抗剂。所述化合物还可以结合肾上腺素能受体α2beta并且是拮抗剂; 或者化合物不是肾上腺素能受体α2beta的拮抗剂，并且化合物与减少或预期降低个体血压的第二药剂一起施用。该化合物可用于治疗，例如调节血糖水平，增加胰岛素分泌并治疗对胰岛素产生增加或预期是响应的疾病或病症。具体描述了化合物治疗2型糖尿病的用途。

3. 发明申请

WO2014022707A1 PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS 审中-公开
标题翻译：制备集成抑制剂的方法和中间体
公开(公告)号：WO2014022707A1
公开(公告)日：2014-02-06
申请号：PCT/US2013/053295
申请日：2013-08-01
申请人： GILEAD SCIENCES, INC.
发明人： PCION, Dominika , TOMASI, Carrie , WHITCOMB, Mark, Charles , DOWDY, Eric, D. , FU, Wenyi , MACLEOD, Patricia
IPC分类号： C07D215/56 , C07C43/29 , C07C49/84
CPC分类号： C07D215/56 , C07C43/225 , C07C45/30 , C07C45/46 , C07C49/84 , C07C67/12 , C07C67/343 , C07C69/738
摘要： The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.
摘要翻译：本发明提供可用于制备具有有用的整合酶抑制性质的4-氧喹诺酮化合物的合成方法和合成中间体。

4. 发明申请

WO2013090032A1 PROCESS FOR THE SEPARATION OF MONO-AND DI-CARBOXYLIC ACID COMPOUNDS 审中-公开
标题翻译：分离单 - 和二 - 羧酸化合物的方法
公开(公告)号：WO2013090032A1
公开(公告)日：2013-06-20
申请号：PCT/US2012/067436
申请日：2012-11-30
申请人： RENNOVIA, INC.
发明人： ARCHER, Raymond , DIAMOND, Gary, M. , DIAS, Eric, L. , MURPHY, Vincent, J. , PETRO, Miroslav , SUPER, John, D.
IPC分类号： B01D15/36 , C07C51/47 , C08G69/00
CPC分类号： C07C51/377 , B01D15/16 , B01D15/1821 , B01D15/185 , B01D15/363 , C07C51/47 , C07C53/08 , C07C59/285
摘要： The present disclosure relates to processes for the separation of at least one di-carboxylic acid compound and/or at least one mono-carboxylic acid compound from a mixture. The separation processes involve contacting the mixture with an ion exchange medium to cause at least one of the mono- and/or di-carboxylic acid compounds to be retained by the medium, eluting at least one of the mono-carboxylic acid compound or the di-carboxylic acid compound using an eluent to form an eluate, wherein the eluate is enriched in at least one of the the mono-carboxylic acid compound or di-carboxylic acid relative to the concentration of such eluted acid in the mixture having contacted the medium and wherein the eluent comprises an organic acid. The process has particular utility in the production of di-carboxylic acid compounds from glucose.
摘要翻译：本公开涉及从混合物中分离至少一种二羧酸化合物和/或至少一种单羧酸化合物的方法。分离过程包括使混合物与离子交换介质接触以使至少一种单羧酸化合物和/或二羧酸化合物由介质保留，至少一种单羧酸化合物或二 - 羧酸化合物，使用洗脱剂形成洗脱液，其中相对于接触介质的混合物中这种洗脱酸的浓度，洗脱液富含至少一种单羧酸化合物或二羧酸，和其中洗脱液包含有机酸。该方法在从葡萄糖生产二羧酸化合物中具有特殊的用途。

5. 发明申请

WO2013086454A1 LED BULB WITH LIQUID-COOLED DRIVE ELECTRONICS 审中-公开
标题翻译：带有液体冷却驱动电子的LED灯泡
公开(公告)号：WO2013086454A1
公开(公告)日：2013-06-13
申请号：PCT/US2012/068623
申请日：2012-12-07
申请人： SWITCH BULB COMPANY, INC.
发明人： LE TOQUIN, Ronan , HORN, David , TITZLER, David
IPC分类号： H01L23/44
CPC分类号： F21K9/23 , F21K9/232 , F21K9/238 , F21V3/061 , F21V3/062 , F21V23/006 , F21V29/506 , F21V29/58 , F21V29/77 , F21Y2115/10 , Y10T29/49117
摘要： A liquid-filled light emitting diode (LED) bulb including a stem body, a shell connected to the stem body to form an enclosed volume, and one or more LEDs attached to a support structure and disposed between the shell and the stem body. The LED bulb also includes a driver circuit configured to electrically drive the one or more LEDs. A thermally conductive liquid and a liquid-volume compensation mechanism are also disposed with the enclosed volume. The one or more LEDs and the driver circuit are thermally coupled to the thermally conductive liquid.
摘要翻译：一种充满液体的发光二极管（LED）灯泡，其包括茎体，连接到茎体以形成封闭容积的壳体，以及连接到支撑结构并设置在壳体和茎体之间的一个或多个LED。 LED灯泡还包括被配置为电驱动一个或多个LED的驱动器电路。导热液体和液体体积补偿机构也与封闭体积一起设置。一个或多个LED和驱动电路热耦合到导热液体。

6. 发明申请

WO2009111543A3 TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS 审中-公开
公开(公告)号：WO2009111543A3
公开(公告)日：2009-09-11
申请号：PCT/US2009/035996
申请日：2009-03-04
申请人： EDISON PHARMACEUTICALS, INC. , MILLER, Guy, M.
发明人： MILLER, Guy, M.
IPC分类号： A61K38/00
摘要： Compositions and methods are provided for prophylactic or therapeutic treatment of a mammal for hearing or balance impairments involving neuronal damage, loss, or degeneration, by administration of a therapeutically effective amount of a redox- active therapeutic. Also provided are improved compositions and methods for treatments requiring administration of a pharmaceutical having an ototoxic side-effect in combination with a therapeutically effective amount of a redox-active therapeutic to treat the ototoxicity.

7. 发明申请

WO2015048336A3 MARKERS FOR AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND PRESYMPTOMATIC ALZHIMER'S DISEASE (PSAD) 审中-公开
公开(公告)号：WO2015048336A3
公开(公告)日：2015-04-02
申请号：PCT/US2014/057530
申请日：2014-09-25
申请人： INSTITUTE FOR SYSTEMS BIOLOGY
发明人： SMITH, Jennifer, Joy , DANZIGER, Samuel, Anthony , AITCHISON, John, David , MILLER, Leslie, Rae
IPC分类号： C12Q1/02 , C12Q1/68 , C12N5/00 , C07H21/04
摘要： Methods to detect amyotrophic lateral sclerosis (ALS) or presymptomatic Alzheimer's disease (PSAD) using an indicator cell assay platform (iCAP) in a test subject are described. Specifically, the disclosure provides a method comprising contacting a biological fluid of said test subject with indicator cells and assessing said indicator cells for the level of expression of an exon of CKIgamma2 that encodes the C-terminal palmitoylated region of said CKIgamma2, to determine the probability that a test subject is afflicted with amyotrophic lateral sclerosis (ALS). Further disclosed are methods of using indicator cells that are pan neuronal populations of glutamatergic (and/or GABAergic) neurons to determine the probability of the presence of presymptomatic or symptomatic Alzheimer's disease (PSAD) in a test subject.

8. 发明申请

WO2013173372A1 REDUCTION CATALYSTS 审中-公开
标题翻译：还原催化剂
公开(公告)号：WO2013173372A1
公开(公告)日：2013-11-21
申请号：PCT/US2013/040997
申请日：2013-05-14
申请人： RENNOVIA, INC.
发明人： SALEM, George, Fredrick , ZHU, Guang , HAGMEYER, Alfred, Gerhard , DIAS, Eric, L.
IPC分类号： B01J37/02 , B01J21/06 , B01J23/46 , B01J35/10 , B01J23/40 , C07C51/377 , C07C55/14
CPC分类号： B01J23/464 , B01J21/063 , B01J21/066 , B01J21/18 , B01J23/40 , B01J23/58 , B01J29/04 , B01J35/1014 , B01J35/1061 , B01J35/1066 , B01J37/0205 , B01J37/024 , C07C51/377 , C07C55/14
摘要： Disclosed are catalysts comprised of platinum and rhodium on a support selected from the group of zirconia, stabilized (doped) zirconia, zirconia-metal oxide composites, and mixtures thereof, wherein the outer surfaces of the support are selected from the group of zirconia, stabilized zirconia, and mixtures thereof. The catalysts are generally useful for the selective hydrodeoxygenation of carboxylic acids containing at least one additional hydroxyl group along the backbone thereof. More particularly, the catalysts are supported catalysts comprising platinum and rhodium, wherein the molar ratio of platinum to rhodium is in the range of about 3:1 to about 1:2. The average pore diameter of the catalyst supports is in the range of from about 5 nm to about 70 nm and the surface area is in the range of from about 15 m 2 /g to about 200 m 2 /g. Also disclosed are methods for the hydrodeoxygenation of carboxylic acids, mono- and/or di-lactones thereof having at least one hydroxyl group on the backbone thereof to corresponding acids where the backbone hydroxyl group has been reduced in the presence of the catalyst. Further disclosed is a process of producing an adipic acid product at a yield of at least about 80%.
摘要翻译：公开了由选自氧化锆，稳定（掺杂）氧化锆，氧化锆 - 金属氧化物复合物及其混合物的载体上的铂和铑组成的催化剂，其中载体的外表面选自氧化锆，稳定的氧化锆及其混合物。催化剂通常可用于沿其主链含有至少一个另外的羟基的羧酸的选择性加氢脱氧。更具体地，催化剂是包含铂和铑的载体催化剂，其中铂与铑的摩尔比在约3:1至约1:2的范围内。催化剂载体的平均孔径在约5nm至约70nm的范围内，表面积为约15m 2 / g至约200m 2 / g。还公开了羧酸，其在主链上具有至少一个羟基的单 - 和/或二 - 内酯加氢脱氧的方法，其中在催化剂存在下骨架羟基已被还原的相应的酸。进一步公开的是以至少约80％的产率生产己二酸产物的方法。

9. 发明申请

WO2013090031A2 WATER CONCENTRATION REDUCTION PROCESS 审中-公开
标题翻译：水浓缩还原过程
公开(公告)号：WO2013090031A2
公开(公告)日：2013-06-20
申请号：PCT/US2012/067424
申请日：2012-11-30
申请人： RENNOVIA, INC.
发明人： ARCHER, Raymond , DIAMOND, Gary, M. , DIAS, Eric, L. , MURPHY, Vincent, J. , PETRO, Miroslav , SUPER, John, D.
IPC分类号： C07C51/347 , C07C51/09
CPC分类号： C07C51/347 , C07C51/09 , C07C51/377 , C07C51/412 , C07C209/00 , C07C55/14 , C07C211/12
摘要： The present disclosure relates generally to water concentration reduction processes within an adipic acid process. The present invention also includes process for converting a glucose-containing feed derived from a carbohydrate source to an adipic acid product wherein the process includes the steps of: converting glucose in the feed to a reaction product including a hydrodeoxygenation substrate and a first concentration of water; reducing the concentration of water in the reaction product to produce a feedstock including the hydrodeoxygenation substrate and second concentration of water, wherein the second concentration of water is less than the first concentration of water; and converting at least a portion of the hydrodeoxygenation substrate in the feedstock to an adipic acid product. Processes are also disclosed for producing hexamethylene diamine and caprolactam from the adipic acid product.
摘要翻译：本公开一般涉及己二酸工艺内的水浓度降低过程。本发明还包括将源自碳水化合物源的含葡萄糖的进料转化为己二酸产物的方法，其中该方法包括以下步骤：将进料中的葡萄糖转化为包含加氢脱氧底物和第一浓度的水的反应产物 ; 降低反应产物中水的浓度以产生包含加氢脱氧基质和第二浓度水的原料，其中第二浓度的水小于第一浓度的水; 和将原料中的加氢脱氧基质的至少一部分转化成己二酸产物。还公开了从己二酸产品生产六亚甲基二胺和己内酰胺的方法。

10. 发明申请

WO2011011453A2 PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES 审中-公开
标题翻译：表型肿瘤浸润性白血病
公开(公告)号：WO2011011453A2
公开(公告)日：2011-01-27
申请号：PCT/US2010/042654
申请日：2010-07-20
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , UNIVERSITY COLLEGE DUBLIN , COUSSENS, Lisa, M. , DENARDO, David, G. , BRENNAN, Donal, J.
发明人： COUSSENS, Lisa, M. , DENARDO, David, G. , BRENNAN, Donal, J.
IPC分类号： G01N33/574 , C07K16/30 , A61K39/395 , A61P35/00
CPC分类号： G01N33/57492 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , G01N33/57415 , G01N33/57449 , G01N2333/70514 , G01N2333/70517 , G01N2333/70596 , G01N2800/54
摘要： The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient.
摘要翻译：本公开涉及肿瘤浸润白细胞的免疫特征。具体而言，本公开内容提供了用于确定肿瘤浸润白细胞的免疫特征的方法和试剂盒，用于评估癌症复发和长期存活的风险，以及用于开发癌症患者的治疗方案。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式